• <table id="gigg0"></table>
  • west china medical publishers
    Keyword
    • Title
    • Author
    • Keyword
    • Abstract
    Advance search
    Advance search

    Search

    find Keyword "阿米卡星" 4 results
    • Injuries of Tracheal Mucosal Surface Structure Caused by Amikacin and Interference Effects of Ambroxol

      Objective To observe the effects of ambroxol injection on mucosal surface structure of trachea injured by intratracheal instillation of amikacin. Methods 280 Wistar rats were randomly divided into four groups( n = 70 in each group) , ie. a normal control group, a normal saline group( intratracheally instilled normal saline) , an amikacin group ( intratracheally instilled amikacin) , and an ambroxol group ( intratracheally instilled amikacin and ambroxol simultaneously) . At the time points of 2, 12, 24, 48, 72 hours six animals in each group were killed and the samples of 1/3 lower segment of trachea were collected and observed by scanning electron microscope. Endotracheal intubation were made on other 6 animals to collecte broncho-alveolar lavage fluid ( BALF) for leucocyte count. Results Compared with the normal control group, elevated leucocyte count was observed in all other groups, various grades of swelling of the cilia were revealed, followed by more or less cilia laid flat with adjacent cilia conglutinated. Then partial cell membrane on top of some cilia bulged out. In terms of injury, the normal saline group was the most mild, and the amikacin group was most serious with the highest leucocyte count. All the parameters were relieved in ambroxol group. Conclusions Intratracheal instillation of amikacin causes acute injury of the ultrastructure of mucosal surface cilia. Ambroxol can promote the recovery process and alleviate inflammation of airway.

      Release date: Export PDF Favorites Scan
    • 頭孢吡肟聯合阿米卡星治療血液腫瘤粒缺期細菌性肺炎的療效觀察

      目的:觀察頭孢吡肟聯合阿米卡星治療血液腫瘤粒缺期細菌性肺炎的療效和不良反應。方法:120例入選患者隨機分為治療組和對照組,每組60例,分別接受頭孢吡肟聯合阿米卡星及頭孢他啶聯合阿米卡星治療。其中,頭孢吡肟或頭孢他啶均為2g加入生理鹽水100mL,每日2次,靜脈點滴;阿米卡星0.4g,加入生理鹽水500mL中,每日1次,靜脈點滴,治療持續一般1~2周。采用衛生部1993年抗菌藥物臨床研究指導原則進行判斷療效.結果:治療組與對照組有效率分別為80%、76.7%,細菌清除率分別為91.9%、90.2%。兩組比較差異無統計學意義(Pgt;0.05)。兩組患者共分離出病原菌123株,藥敏試驗顯示對頭孢吡肟的敏感率為90.2%,顯著高于頭孢他啶69.7%,差異有統計學意義(Plt;0.01)。不良反應主要有惡心及皮疹等,均可耐受。發生率分別為5%和11%,兩組比較差異無統計學意義(Pgt;0.05)。結論:頭孢吡肟聯合阿米卡星治療血液腫瘤粒缺期細菌性肺炎的療效略優于頭孢他啶組,體外抗菌活性顯著優于頭孢他啶組。

      Release date:2016-09-08 09:56 Export PDF Favorites Scan
    • Protective Effects of Ambroxol on Tracheal Mucosa of Rats Injured by Intratracheally Instilled Amikacin

      Objective To investigate the effects of ambroxol hydrochloride on surface structure of trachea mucosa in rats injured by intratracheally instilled amikacin. Methods Thirty Wistar rats injured by intratracheally instilled amikacin ( 0. 252 mL/kg) were randomly divided into a control group ( n =15) and an ambroxol group ( n= 15) . The rats in the ambroxol group were intraperitoneally injected with ambroxol hydrochloride ( 70 mg/kg) 5 minutes after amikacin administration. They were all equally divided into five subgroups and sacrificed at 2, 4, 8, 28, 48 hours respectively. Then the samples of 1/3 lower segment of trachea were collected and observed under scanning electron microscope. Results In the control group, the mucous secretion and its stickness were increased. The cilia were found lodged, sticked together, aligned abnormally, abrupt partly, and recovered slowly, with the percentage of damaged area of 98. 2% , 98. 5% , 97. 5%, 92. 7% , 82. 1% at 2, 4, 8,24,48 h, respectively. The injuries of mucosa in the ambroxol group were much milder and recovered more rapidly than those in the control group, with the percentage of damaged area of 85. 7% , 81. 9% , 73. 0% , 61. 9% , 50. 2% at 2, 4, 8, 24, 48 h, respectively. Conclusions Intratracheal instillation of amikacin can cause cilia ultrastructure damage on tracheal mucosa. Ambroxol can promote the recovery process and alleviate airway inflammation.

      Release date:2016-09-13 04:07 Export PDF Favorites Scan
    • 抗菌藥物對銅綠假單胞菌引起的呼吸機相關性肺炎患者下呼吸道菌群變化的影響

      目的探討由銅綠假單胞菌引起的呼吸機相關性肺炎(VAP)患者經抗菌藥物治療后,其下呼吸道菌群的變化情況。 方法納入濟寧市第一人民醫院重癥醫學科(ICU)2010年9月至2012年9月間培養出銅綠假單胞菌且臨床肺部感染評分≤6分的54例VAP患者。將患者隨機分為抗菌藥物組(頭孢他啶+阿米卡星,n=28)與對照組(n=26),治療7 d后,再次行下呼吸道分泌物培養,分別觀察兩組未培養出細菌(培養陰性率)以及轉變為其他細菌的例數(菌群變化率)。 結果抗菌藥物組中細菌培養陰性者10例(占35.7%),菌群變化者11例(占39.3%,且包含2例多重耐藥銅綠假單胞菌)。對照組中細菌培養陰性者11例(占42.3%),菌群變化者3例(占11.5%)。兩組間細菌培養陰性率差異無統計學意義(35.7%比42.3%,P>0.05),而抗菌藥物組菌群變化率則明顯高于對照組(39.3%比11.5%,P < 0.05)。 結論在銅綠假單胞菌引起的臨床肺部感染評分≤6分的VAP患者,經抗菌藥物治療后易導致其下呼吸道菌群發生變化,甚至多重耐藥菌的出現。

      Release date:2016-10-10 10:33 Export PDF Favorites Scan
    1 pages Previous 1 Next

    Format

    Content

  • <table id="gigg0"></table>
  • 松坂南